查看文章

Since the development of CRISPR–Cas as a tool for targeted genome manipulation in 2012, genome editing has revolutionized basic and translational research around the globe 1. The technology and its potential in bio-innovation were recently highlighted with the approval of the first CRISPR–Cas-based gene therapies for sickle cell anemia and β-thalassemia in humans. However, genome editing is currently underexplored in Africa, where it could be transformative in addressing key challenges in major sectors (including agriculture, public health and medicine) 2 (Fig. 1).

Similar to other biotechnologies, genome editing faces substantial obstacles in Africa. These include regulatory uncertainty, limited access to laboratories, equipment and reagents for molecular biology work, a shortage of trained professionals, and a low rate of returnees among the diaspora. There is also little investment: most countries devote …